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Article / Clinical Case Report
ABSTRACT
Tailgut cysts (TGCs) are rare congenital entities arising from remnants of the embryological postanal primitive gut. 
Malignancy in TGCs is rare, with the majority being adenocarcinomas and carcinoid tumors. A search of the published 
literature yielded only 27 cases of adenocarcinoma developing in TGCs. We described the case of a 54-year-old female 
who presented with complaints of pelvic and perineal pain of several weeks. After the initial work-up, a mass in the right 
presacral location was diagnosed. She underwent radical resection of the tumor, using a posterior approach. The lesion 
was removed en bloc with the middle rectum, coccyx, and sacrum (S4–S5). The histopathologic examination revealed 
an adenocarcinoma arising in a TGC, and the patient received adjuvant chemoradiotherapy. Our case underlines that 
diagnosing a TGC is difficult as it is a rare congenital lesion. Clinical examination may be challenging as TGCs present 
with various symptoms, which can mimic other commonly proctologic disorders. Patients should be referred to a tertiary 
center with experience in pelvic surgery and must be managed by a multidisciplinary approach to maximize successful 
treatment. The recommended treatment is surgical excision given the malignant potential of TGCs and their risk of 
causing local complications. 
Keywords 
Cysts; Adenocarcinoma; Congenital Abnormalities; Pelvic Neoplasms
INTRODUCTION
Tailgut cysts (TGCs) are rare congenital entities 
arising from remnants of the embryological postanal 
primitive gut. The majority of TGCs are benign lesions 
located in the retrorectal space. This space is defined 
anteriorly by the rectum, posteriorly by the sacrum, 
superiorly by the peritoneal reflection, inferiorly by 
the levator ani and coccygeus muscle, and laterally 
by the ureter and iliac vessels. Malignancy in TGCs is 
rare, with the majority being adenocarcinomas and 
carcinoid tumors. A search of the published literature 
yielded only 27 cases of adenocarcinoma developing in 
TGCs.1-22 The reported cases were identified using the 
electronic database search on PubMed (January 1970 
to July 2018). The following free text terms were used: 
“tailgut cyst”, “retrorectal”, and “adenocarcinoma”. 
The reference lists of published studies were also 
reviewed to find additional cases.
CASE REPORT
A 54-year-old female presented with complaints 
of pelvic and perineal pain of several weeks’ duration. 
No history of urinary complaints or difficulties in 
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defecation were reported. On physical examination, 
there was no abnormality. Proctosigmoidoscopy 
revealed a bulging of the rectal wall in the middle 
rectum, 7 cm from the anal margin, with suprajacent 
normal mucosa. Further work-up included a pelvic 
magnetic resonance imaging (MRI), which revealed 
a mass in the right presacral space, with lobulated 
contours and soft tissue density (Figure 1).
The mass measured 5 × 3 × 3.5 cm (longitudinal, 
transverse, and antero-posterior axis, respectively) 
and exhibited a heterogeneous signal intensity. After 
administration of intravenous contrast, a heterogeneous 
enhancement was observed, which persisted in 
the late phase. The neoplasm had characteristics 
of aggressiveness, with infiltration of the adjacent 
sacrum. However, the rectal mucosa was found to be 
intact and the fat plane was preserved within the rectal 
ampulla. Computed tomography (CT)-guided biopsy 
(18G) revealed fibrous tissue of desmoplastic aspect, in 
which intestinal-like adenocarcinoma structures were 
identified. A staging CT scan did not show any evidence 
of distant metastases. The patient underwent en bloc 
resection of the tumor using a posterior approach 
(Kraske procedure). During surgery, we found a mass 
present in the retrorectal space. It  was adherent to and 
not easily separated from the rectum and the perirectal 
fat. The mass was carefully dissected and removed 
intact in a block with the middle rectum, coccyx, and 
sacrum to the level of S4. On gross examination, the 
resected specimen measured 8.8 cm × 7.5cm × 8.5 cm, 
and included a 4.9 cm × 4 cm × 3 cm whitish and 
hardened neoplasia (Figure 2).
It contained a multiloculated cystic area, with 
brownish content. The histopathologic evaluation 
revealed the presence of a malignant neoplasm with 
a predominantly intestinal pattern of adenocarcinoma 
(Figure 3A and 3B). This neoplasm coexists with a 
multiloculated cystic lesion, covered by a columnar-type 
epithelium, focally sketching micropapillae with 
areas of low- and high-grade dysplasia (Figure 3D). 
It had an infiltrative growth pattern and invaded the 
adjacent soft tissues (skeletal muscle), and focally, the 
sacrum-but did not reach the rectal wall. It showed 
vascular and perineural invasion. The margins of 
resection were free of the carcinoma with exception 
to the proximal margin (upper pre-sacral soft tissue), 
which was focally involved. An immunohistochemical 
study showed diffuse positivity for CAM 5.2 and CDX2; 
multifocal positivity for CK20; and focal positivity for 
CK7 (Figure 4). Combined with clinical symptoms and 
imaging, a histopathologic diagnosis of adenocarcinoma 
arising in a TGC was established.
Figure 1. Sagittal (A) and axial (B) section of the pelvic MRI showing the tailgut cyst (arrows). MRI = magnetic 
resonance imaging.
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Figure 2. Specimen after surgical excision (A). Gross pathology of the resected specimen on cross sectioning showing 
the tumor and its relationships with adjacent tissues (B) R = Rectum; S = Sacral bone; T = Tumor. Macroscopic 
appearance of tumor within the tail gut cyst (C). Extensive infiltration of pre-sacral soft tissues (D).
Figure 3. Photomicrographs of the tumor showing the morphology of the adenocarcinoma arising within the 
tailgut cyst (A and B). Multiloculated, cystic areas (C). Cyst wall showing the uniform lining of the luminal surface by 
columnar type epithelium with areas of low- and high-grade dysplasia (D).
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The patient’s postoperative recovery was 
complicated with a wound infection, which was 
treated with antibiotics. After evaluation, the 
tumor board decided to advise her for adjuvant 
chemoradiotherapy. She received a dose of 54 Gy/30 
fractions to the pelvis (including sacrum), according 
to the intensity-modulated radiotherapy technique for 
6 weeks, associated with oral capecitabine. Since then, 
the patient has had regular visits to our department 
and remains without relapse, 11 months after surgery.
DISCUSSION
The retrorectal (or presacral) space is an area of 
growth of multiple embryologic structures that involute 
during embryonic development. Consequently, this 
space can harbor a heterogeneous group of tumors 
(both benign and malignant) originating from the 
embryologic remnants.
Retrorectal tumors are rare and their incidence in 
the general population is unknown, generally because 
most cases are concentrated in tertiary centers. 
Hobson et al.23 reported that a surgeon practicing 
outside the setting of a major referral center can expect 
to see, on average, at least one patient with a presacral 
tumor during the course of a typical career.
The classification system proposed by Dozois et al.24 
from the Mayo Clinic is the most commonly used. 
According to this classification, tumors are divided 
into five categories: congenital, neurogenic, osseous, 
inflammatory, or miscellaneous, which are further 
grouped into benign and malignant.
The most frequent lesions in children are 
teratomas, while in adults they are chordoma and 
developmental cysts.3,25 Retrorectal tumors are most 
commonly congenital and benign. Congenital tumors 
have a female predominance, while the other disease 
groups had a similar distribution between the two 
genders. However, malignant tumors occur more 
frequently in men.26
The tailgut is a post-cloacal extension of the 
embryonic gut that normally, by the eighth week 
of embryogenesis, atrophies and the tail involutes.16 
TGC is a rare congenital retrorectal lesion believed to 
derive from vestiges of the embryonic post-anal gut 
(tailgut) that fails to regress completely.
Malignancy in TGCs is a rare phenomenon. 
Malignant neoplasms that have been reported 
within TGCs include adenocarcinomas, carcinoid 
tumors, neuroendocrine carcinomas, endometrioid 
carcinomas, adenosquamous carcinomas, squamous 
cell carcinomas, and sarcomas. The first case of a 
TGC with malignant transformation was described 
by Ballantine in 1932;1 since then, only 27 cases of 
adenocarcinoma developing in TGCs were described 
in the literature.1-22
Symptoms may be due to mass effects, causing 
lower abdominal and back pain, rectal bleeding, 
tenesmus, urinary frequency, rectal fullness, and 
constipation.10 A careful rectal examination is essential 
to the diagnosis in more than 90% of patients.23 
Flexible sigmoidoscopy can determine the involvement 
of the rectal mucosa. Our patient had pelvic pain, a 
symptomatology that is most frequently associated 
with other gynecological and digestive disorders.
Contrast enhanced pelvic MRI is the gold 
standard of the imaging modalit ies currently 
available. MRI appears to have an advantage over 
Figure 4. Photomicrographs of the tumor. Immunohistochemical staining: positivity of CK20 (A), CK7 (B), and 
CDX2 (C).
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the CT scan because of superior soft-tissue contrast 
resolution, which provides improved delineation of 
the anatomic extent of the tumor and superior tissue 
characterization.27 However, the accuracy of an 
MRI and a CT scan for a specific histologic retrorectal 
tumor type was only 28% and 18%, respectively, and 
some authors have advocated that it is not advisable to 
avoid resection based solely on non-invasive studies.28 
In this case, the MRI allowed us to decide the surgical 
approach and to be alert to the potential risk of sacrum 
involvement.
Biopsy of a retrorectal mass is controversial. On the 
one hand, given the limitations of imaging to make a 
definitive diagnosis, percutaneous biopsy of solid or 
heterogeneous presacral tumors could be obtained 
preoperatively to facilitate decision making for the use 
of neoadjuvant therapies and for optimizing surgical 
planning.29 On the other hand, there is the fear that 
it can lead to contamination or tumor spread. Some 
authors only recommend a biopsy to be performed if 
the lesion appears to be unresectable and if a tissue 
diagnosis is required to guide neoadjuvant therapy.26 
In a comprehensive review, 27% of the patients 
underwent biopsy to confirm the diagnosis. Of these 
patients, incorrect diagnoses occurred in 44%.26
This patient had a biopsy before the evaluation 
in our center. In this case, we did not think that the 
biopsy was necessary since it was a clearly resectable 
lesion. The result of the biopsy would not change the 
future management and eventually could increase the 
risk of infection.
There is no consensus on management for TGC 
adenocarcinoma because of the very low incidence 
rate. Surgery is the mainstay of treatment. Early surgical 
excision is recommended for two reasons: (i) to enable 
a diagnose of malignancy; and (ii) to allow definitive 
treatment and elimination of the risk of complications.8
The common surgical approaches include the 
anterior transabdominal approach, the posterior 
approach (perineal, trans-sacral), and the combined 
approach. Low-lying lesions can be removed via the 
posterior approach. Tumors above the level of S3 
can be resected via the anterior trans-abdominal or 
the combined approach. The rate of postoperative 
complications after resection of a retrorectal tumor is 
estimated to be 45%.30
A significant number of cases described in the 
literature had a poor prognosis due to local recurrence 
and distant metastasis. This fact has favored the 
aggressive surgical treatment of TGCs. For the same 
reason, in some cases, adjuvant radiation therapy with 
or without chemotherapy has been employed with 
good outcomes.8,17
This case highlights the importance of TGC as a 
differential diagnosis of presacral masses, underscoring 
that malignant transformation can occur and may 
result in mortality and morbidity if surgery is not 
carried out.
Diagnosing TGC can be challenging because 
of the lack of familiarity with this entity due to its 
rarity. The clinical features do not follow a standard 
presentation and can mimic other commonly occurring 
proctologic disorders. MRI is indispensable in the 
evaluation of this lesion, showing the size, extension, 
and invasion of adjacent organs, which helps the 
clinician to choose the best surgical approach.
Patients should be referred to a tertiary center 
with experience in pelvic surgery and must be managed 
by a multidisciplinary team to maximize successful 
diagnosis and treatment.
REFERENCES
1. Ballantyne EW. Sacrococcygeal tumors: adenocarcinoma 
of a cystic congenital embryonal remnant. Arch Pathol 
(Chic). 1932;14:1-9.
2. Marco V, Autonell J, Farre J, Fernandez-Layos M, Doncel 
F. Retrorectal cyst-hamartomas. Report of two cases with 
adenocarcinoma developing in one. Am J Surg Pathol. 
1982;6(8):707-14. http://dx.doi.org/10.1097/00000478-
198212000-00002. PMid:7168459.
3. Hjermstad BM, Helwig EB. Tailgut cysts. Report of 53 
cases. Am J Clin Pathol. 1988;89(2):139-47. http://dx.doi.
org/10.1093/ajcp/89.2.139. PMid:3277378.
4. Liessi G, Cesari S, Pavanello M, Butini R. Tailgut cysts: CT 
and MR findings. Abdom Imaging. 1995;20(3):256-8. 
http://dx.doi.org/10.1007/BF00200409. PMid:7620420.
5. Pfannschmidt J, Böttcher H, Hey A, Graf L. Development 
of adenocarcinoma in a retrorectal pre-sacrococcygeal 
hamartoma. Chirurg. 1995;66(7):735-8. PMid:7671763.
6. Levert LM, Van Rooyen W, Van Den Bergen HA. 
Cysts of the tailgut. Eur J Surg. 1996;162(2):149-52. 
PMid:8639730.
7. Lim KE, Hsu WC, Wang CR. Tailgut cyst with 




6-7 Autops Case Rep (São Paulo). 2020 Jan-Mar;10(1):e2019115
8. Maruyama A, Murabayashi K, Hayashi M, et al. 
Adenocarcinoma arising in a tailgut cyst: report of a 
case. Surg Today. 1998;28(12):1319-22. http://dx.doi.
org/10.1007/BF02482826. PMid:9872560.
9. Graadt van Roggen JF, Welvaart K, de Roos A, Offerhaus 
GJ, Hogendoorn PC. Adenocarcinoma arising within a 
tailgut cyst: clinicopathological description and follow 
up of an unusual case. J Clin Pathol. 1999;52(4):310-2. 
http://dx.doi.org/10.1136/jcp.52.4.310. PMid:10474528.
10. Prasad AR, Amin MB, Randolph TL, Lee CS, Ma 
CK. Retrorectal cystic hamartoma: report of 5 cases 
with malignancy arising in 2. Arch Pathol Lab Med. 
2000;124(5):725-9. PMid:10782156.
11. Schwarz RE, Lyda M, Lew M, Paz IB. A carcinoembryonic 
antigen-secreting adenocarcinoma arising within 
a retrorectal  ta i lgut cyst:  c l in icopathological 
considerations. Am J Gastroenterol. 2000;95(5):1344-
7. http://dx.doi.org/10.1111/j.1572-0241.2000.02023.x. 
PMid:10811351.
12. Moreira AL, Scholes JV, Boppana S, Melamed J. p53 
Mutation in adenocarcinoma arising in retrorectal 
cyst hamartoma (tailgut cyst): report of 2 cases–an 
immunohistochemistry/immunoperoxidase study. Arch 
Pathol Lab Med. 2001;125(10):1361-4. PMid:11570917.
13. Andea AA, Klimstra DS. Adenocarcinoma arising in a 
tailgut cyst with prominent meningothelial proliferation 
and thyroid tissue: case report and review of the literature. 
Virchows Arch. 2005;446(3):316-21. http://dx.doi.
org/10.1007/s00428-004-1178-y. PMid:15731926.
14. Cho BC, Kim NK, Lim BJ, et al. A carcinoembryonic 
antigen-secreting adenocarcinoma arising in tailgut cyst: 
clinical implications of carcinoembryonic antigen. Yonsei 
Med J. 2005;46(4):555-61. http://dx.doi.org/10.3349/
ymj.2005.46.4.555. PMid:16127782.
15. Killingsworth C, Gadacz TR. Tailgut cyst (retrorectal cystic 
hamartoma): report of a case and review of the literature. 
Am Surg. 2005;71(8):666-73. PMid:16217950.
16. Tampi C, Lotwala V, Lakdawala M, Coelho K. 
Retrorectal cyst hamartoma (tailgut cyst) with malignant 
transformation. Gynecol Oncol. 2007;105(1):266-
8. http://dx.doi.org/10.1016/j.ygyno.2007.01.008. 
PMid:17303225.
17. Jarboui S, Jarraya H, Mihoub MB, Abdesselem MM, 
Zaouche A. Retrorectal cystic hamartoma associated 
with malignant disease. Can J Surg. 2008;51(6):E115-6. 
PMid:19057717.
18. Mathis KL, Dozois E, Grewal MS, Metzger P, Larson 
DW, Devine RM. Malignant risk and surgical outcomes 
of presacral tailgut cysts. Br J Surg. 2010;97(4):575-9. 
http://dx.doi.org/10.1002/bjs.6915. PMid:20169572.
19. Chhabra S, Wise S, Maloney-Patel N, Rezac C, 
Poplin E. Adenocarcinoma associated with tail 
gut cyst. J Gastrointest Oncol. 2013;4(1):97-100. 
PMid:23450681.
20. Rammeh S, Ben Abdelkrim S, Khalifa MH, Letaief 
R, Mokni M. Adenocarcinoma arising in a tailgut 
cyst: a case report. Pathologica. 2013;105(6):346-8. 
PMid:24730339.
21. Zhao XR, Gao C, Zhang Y, Yu YH. The malignant 
transformation of retrorectal cystic hamartomas with 
blood irregular antibodies positive: a case report. 
Medicine. 2015;94(49):1-3. http://dx.doi.org/10.1097/
MD.0000000000002253. PMid:26656372.
22. Manco G, Giliberti G, Rolando G, Gelsomino F, Zunarelli 
E, Rossi A. Malignant transformation of a tailgut cyst. 
Ann Ital Chir. 2017;6:1-4. PMid:28892466.
23. Hobson KG, Ghaemmaghami V, Roe JP, Goodnight 
JE, Khatri VP. Tumors of the retrorectal space. Dis 
Colon Rectum. 2005;48(10):1964-74. http://dx.doi.
org/10.1007/s10350-005-0122-9. PMid:15981068.
24. Dozois EJ, Jacofsky DJ, Dozois RR. Presacral tumors. In: 
Wolff BG, Fleshman JW, Beck DE, editors. The ASCRS 
textbook of colon and rectal surgery. New York: Springer; 
2007. p. 501-14. http://dx.doi.org/10.1007/978-0-387-
36374-5_36.
25. Uhlig BE, Johnson RL. Presacral tumors and cysts in adults. 
Dis Colon Rectum. 1975;18(7):581-9. http://dx.doi.
org/10.1007/BF02587141. PMid:1181162.
26. Baek SK, Hwang GS, Vinci A, et al. Retrorectal tumors: 
a comprehensive literature review. World J Surg. 
2016;40(8):2001-15. http://dx.doi.org/10.1007/s00268-
016-3501-6. PMid:27083451.
27. Yang B-L, Gu Y-F, Shao W-J, et al. vet al. Retrorectal 
tumors in adults: magnetic resonance imaging findings. 
World J Gastroenterol. 2010;16(46):5822-9. http://
dx.doi.org/10.3748/wjg.v16.i46.5822. PMid:21155003.
28. Glasgow SC, Birnbaum EH, Lowney JK, et al. Retrorectal 
tumors: a diagnostic and therapeutic challenge. Dis Colon 
Rectum. 2005;48(8):1581-7. http://dx.doi.org/10.1007/
s10350-005-0048-2. PMid:15937630.
29. Merchea A, Larson DW, Hubner M, Wenger DE, Rose 
PS, Dozois EJ. The value of preoperative biopsy in the 
management of solid presacral tumors. Dis Colon 
Rectum. 2013;56(6):756-60. http://dx.doi.org/10.1097/
DCR.0b013e3182788c77. PMid:23652750.
30. Jao SW, Beart RW Jr, Spencer RJ, Reiman HM, Ilstrup DM. 
Retrorectal tumors. Mayo Clinic experience, 1960-1979. 
Dis Colon Rectum. 1985;28(9):644-52. http://dx.doi.
org/10.1007/BF02553440. PMid:2996861.
Martins P, Canotilho R, Peyroteo M, Afonso M, Moreira A, Sousa A
7-7Autops Case Rep (São Paulo). 2020 Jan-Mar;10(1):e2019115
Author contributions: Martins PC, Canotilho R, Peyroteo M, Afonso M, Moreira A and Sousa A planned and 
reviewed the article. Martins PC, Canotilho R and Peyroteo M did the literature review and wrote the manuscript. 
All authors collectively approved the manuscript’s final version for publication.
The authors retain an informed consent and the manuscript is in accordance with the procedures and regulations 
of the Institutional Research Ethics Committee.
Conflict of interest: None
Financial support: None
Submitted on: December 22nd, 2018 
Accepted on: February 22nd, 2019
Correspondence 
Pedro Martins 
Instituto Português de Oncologia do Porto FG - EPE - Serviço de Oncologia Cirúrgica 
Rua Júlio Ramos, 4, 3F, Porto – Portugual 
4200-072 
Phone: +35 1914402724 
pedrocm05@gmail.com
